Principal Investigator
Assistant Professor of Medicine (Hematology)
Coraline Mlynarczyk, PhD, is an Assistant Professor of Medicine in Medical Oncology and Hematology, Pathology, and a member of the Center of Molecular and Cellular Oncology (CMCO) at the Yale Cancer Center. She is affiliated with the Biological and Biomedical Sciences Graduate School and her lab studies the immunology and metabolism of germinal center-derived B cell lymphomas. Dr. Mlynarczyk obtained her PhD in Hematology and Oncology (Paris Diderot University & Saint Louis Hospital, France), where she studied how the p53 tumor suppressor pathway diversifies in response to cellular stresses and identified endoplasmic reticulum stress as a condition that can be manipulated to increase cancer cells sensitivity to chemotherapy. During her postdoctoral studies (Weill Cornell Medicine, NYC, lab of Dr. Ari Melnick), she further developed her interest in understanding malignant transformation and treatment failure in the context of B cell lymphomas. Diving into the immunology field, she discovered that aberrant competitive fitness gain in germinal center B cells represents a novel mechanism for their malignant transformation, yielding aggressive and disseminated B cell lymphomas in mice and humans. She received support from the Lymphoma Research Foundation (LRF), Leukemia & Lymphoma Society (LLS) and American Association of Hematology (ASH) for her postdoctoral research and was promoted to Instructor of Cancer Immunology in Medicine (Weill Cornell Medicine, NY). Dr Mlynarczyk launched her lab at Yale in July 2024. Combining elegant multi-allelic mouse models, patient-derived models and primary samples with precise immunological approaches and metabolic flux analyses, her research aims to provide a better mechanistic and biological understanding of germinal center-derived B cell malignancies, to help identify previously unexplored vulnerabilities of clinically unfavorable B cell lymphomas. The lab's research is currently supported by the American Cancer Society (ACS), the Mark Foundation for Cancer Research and Follicular Lymphoma Foundation.